NCT00234858View on ClinicalTrials.gov

Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

PHASE4CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

April 30, 2006

Conditions
HypertensionMetabolic Syndrome
Interventions
DRUG

trandolapril/verapamil

2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD

DRUG

(Hyzaar) losartan/hydrochlorothiazide

50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00234858 - Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR) | Biotech Hunter | Biotech Hunter